Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer.

Abstract

The chemokine receptor CXCR4 has been reported to be aberrantly expressed in human cancers and has also been shown to participate in the development of cancer metastasis. The present study was carried out to assess immunohistochemically the pattern of CXCR4 expression in patients with metastatic prostate cancer. We analyzed whether there may be an association between CXCR4 expression and prognosis. Fifty-two patients who received hormonal therapy were enrolled. Specimens were obtained from transperineal needle biopsy before treatment, and were stained with antihuman CXCR4 antibody. We also evaluated the pathological grade, extent of bony metastasis, clinical response to hormonal therapy, and patient prognosis. CXCR4 was detected in 94.2% patients. Its expression showed no association with pathological grade, extent of bony metastasis, or clinical response to hormonal therapy. Patients with a high expression of CXCR4 in tumors had poorer cancer-specific survival than those with low expression of CXCR4. CXCR4 expression is a useful prognostic factor for patients with metastatic prostate cancer treated with androgen-withdrawal therapy.

• Authors: Takuya Akashi, Keiichi Koizumi, Koichi Tsuneyama, Ikuo Saiki, Yasuo Takano, Hideki Fuse
• Journal: Cancer science (Cancer Sci) Vol. 99 Issue 3 Pg. 539-42 (Mar 2008) ISSN: 1349-7006 [Electronic] England
• PMID: 18201276 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents, Hormonal
• Biomarkers, Tumor
• Receptors, CXCR4

Topics

• Aged
• Aged, 80 and over
• Antineoplastic Agents, Hormonal (therapeutic use)
• Biomarkers, Tumor (metabolism)
• Bone Neoplasms (pathology, secondary)
• Humans
• Immunohistochemistry
• Male
• Middle Aged
• Multivariate Analysis
• Prognosis
• Prostatic Neoplasms (diagnosis, drug therapy, pathology)
• Receptors, CXCR4 (metabolism)
• Survival Analysis